Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
0.8345
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clearmind Medicine Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Curious about the stocks that are showing activity after the closing bell on Thursday?
↗
April 16, 2026
Via
Chartmill
These stocks are moving in today's session
↗
April 15, 2026
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Topics
Artificial Intelligence
These stocks have an unusual volume in today's session
↗
April 15, 2026
On Wednesday, there are stocks with unusual volume. Let's take a look.
Via
Chartmill
Topics
Artificial Intelligence
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
April 15, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Top stock movements in today's session.
↗
April 14, 2026
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
Topics
Artificial Intelligence
These stocks are moving in today's session
↗
April 14, 2026
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Topics
Artificial Intelligence
Tuesday's session: gap up and gap down stocks
↗
April 14, 2026
Let's have a look at the gap up and gap down stocks in today's session.
Via
Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
↗
April 14, 2026
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via
Chartmill
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
April 14, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Discover the top movers in Friday's pre-market session.
↗
April 10, 2026
Wondering what's happening in Friday's pre-market session? Find an overview in this article.
Via
Chartmill
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
March 30, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
March 27, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
March 19, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
March 17, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
March 13, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
March 11, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 10, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
March 04, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
February 09, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
February 06, 2026
From
Polyrizon Ltd.
Via
GlobeNewswire
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
February 06, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
February 03, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
January 20, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
January 14, 2026
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 31, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
December 24, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
December 16, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
December 12, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
December 12, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-12-11: top gainers and losers in today's session.
↗
December 11, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
